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Available online 29 November 2011Background: Several lines of evidence implicate 5-hydroxytryptamine (5-HT, serotonin) in the
pathophysiology of mood disorders and suicide. However, it is unclear whether these conditions
include morphological involvement of the dorsal raphe nucleus (DRN), the origin of most fore-
brain 5-HT innervation.
Method:We used morphometric, immunohistochemical, and molecular methods to compare the
DRN in post-mortem tissue of 50 subjects (13 controls, 14 major depressive disorder [MDD], 13
bipolar disorder, 10 schizophrenia; 17 of the cases died by suicide). NeuN and PH8 antibodies
were used to assess all neurons and serotonergic neurons respectively; 5-HT1A autoreceptor
expression was investigated by regional and cellular in situ hybridization. Measurements were
made at three rostrocaudal levels of the DRN.
Results: In MDD, the area of the DRN was decreased. In bipolar disorder, serotonergic neuronal
sizewas decreased. Suicide was associatedwith an increased DRN area, andwith a higher density
but decreased size of serotonergic neurons. Total neuronal density and 5-HT1A receptor mRNA
abundance were unaffected by diagnosis or suicide. No changes were seen in schizophrenia.
Conclusion: The results show that mood disorders and suicide are associated with differential,
limited morphological alterations of the DRN. The contrasting influences of MDD and suicide
may explain some of the discrepancies between previous studies, since their design precluded
detection of the effect.






The 5-hydroxytryptamine (5-HT; serotonin) neurons that in-
nervate the forebrain lie in the rostral raphe nuclei of the brain-
stem (Hornung, 2003; Molliver, 1987), with the dorsal raphe
(DRN) being the largest nucleus (Baker et al., 1991). The DRN
provides the main input to the frontal cortex (McQuade and
Sharp, 1997) and an enlarged lateral subdivision characterises
primates, including man (Hornung, 2003). In the DRN cellsHarrison).
ital Site, Oxford OX3
cense.projecting to prefrontal cortex are preferentially found in more
rostral, medial, and ventral subdivisions, and around half are
non-serotonergic (Del Cid-Pellitero and Garzón, 2011; Wilson
andMolliver, 1991). Afferent projections to the DRN are primar-
ily from the limbic system (Hornung, 2003) but there is also a re-
ciprocal innervation of the DRN from prefrontal cortex which
modulates neuronal activity (Celada et al., 2001).
The 5-HT system has been implicated in many psychiatric
disorders, including mood disorders (Barton et al., 2008;
Deakin, 1998; Jans et al., 2007; Mahmood and Silverstone,
2001), and in suicide (Ernst et al., 2009; Mann et al., 1989;
Placidi et al., 2001). The evidence is diverse, and includes alter-
ations in 5-HT metabolism, 5-HT receptors and transporters,
and associations with serotonergic gene polymorphisms.
There is also evidence of decreased neuronal density and
Table 1
Demographics of subjects studied.
Control Schizophreniaa Bipolar disorderb Major depression
Subjects 13 10 13 14
Age (years) 48.7 (10.8) 43.2 (13.0) 42.4 (12.2) 46.6 (9.7)
Sex (M, F) 8, 5 8, 2 8, 5 8, 6
Brain pH 6.25 (0.24) 6.12 (0.29) 6.17 (0.25) 6.19 (0.22)
Fresh brain weight (g) 1521 (167) 1516 (98) 1444 (180) 1439 (133)
Freezer storage (months)c 92.7 (8.1) 102.1 (5.6) 102.8 (4.7) 95.6 (10.0)
Suicides 0 3 8 6
Onset of illness (years) – 22.9 (8.0) 21.4 (8.9) 34.4 (13.7)
Duration of illness (years) – 21.0 (10.7) 21.6 (9.7) 12.3 (11.4)
Lifetime antipsychotic dosed 0 47,800 (54,788) 23,492 (6868) 0
Antipsychotics ever 0 10 11 0
Antidepressants ever 0 3 6 9
Mood stabilisers ever 0 0 8 2
Current substance abuse or dependence 0 2 4 3
Values are mean (S.D.) where appropriate.
a Subtypes: paranoid (n=2), undifferentiated (n=8).
b 10 subjects had psychotic features.
c Differs between groups (ANOVA p=0.003; controlsbschizophrenia (p=0.005) and bipolar disorder (p=0.001).
d Fluphenazine equivalents (g).
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suicides (Underwood et al., 2011).
In contrast, the morphology and cytoarchitecture of the DRN
in these disorders have received limited attention. The existing
studies have utilised conventional stains (Baumann et al., 2002;
Underwood et al., 1999), or antibodies detecting tryptophan hy-
droxylase (TPH) to identify 5-HT neurons (Hendricksen et al.,
2004; Syed et al., 2005; Underwood et al., 1999); there are also
studieswhich have used other 5-HTmarkers (e.g. 5-HT1A autore-
ceptors; Arango et al., 2001; Boldrini et al., 2008; Stockmeier et
al., 1998), or a marker of raphe neuron ‘activation’ (Bielau et al.,
2005). The studies have produced variable results, likely reflect-
ing bothmethodological and clinical factors. For example, aswell
as measuring different parameters, and using various DRN sam-
pling strategies, the studies are small, and differ in the subjects’
age, polarity of mood disorder, and presence of comorbid
conditions.
This investigationwas performed to help shed some further
light on the involvement of the DRN in the neuropathology of
mood disorder and suicide. It has a larger sample size than
existing studies; it includes patients from three diagnostic
groups (major depression [MDD], bipolar disorder, and schizo-
phrenia, as well as suicides and non-suicides within each
group), and uses three complementary techniques:NeuN to as-
sess all neurons, and TPH immunohistochemistry and 5-HT1AR
mRNA in situ hybridization (ISH) as markers of serotonergic
neurons.Table 2
Density of NeuN-labelled neurons in the DRN.
Controls Schizophrenia Bipolar disorder
Level Mean (SEM) N Mean (SEM) N Mean (SEM) N
1 26.1 (1.8) 8 20.2 (3.8) 8 22.0 (2.5) 11
2 28.2 (1.8) 10 21.2 (3.6) 5 26.4 (3.6) 6
3 31.7 (3.1) 7 29.5 (3.1) 6 27.8 (4.5) 5
Values are cells per mm2. There are no significant differences between groups.
a Excludes normal controls.2. Materials and methods
2.1. Subject and tissue characteristics
Unfixed frozen 14 μm sections of brainstem were provided
by the Stanley Neuropathology Consortium from their series
of 60 subjects diagnosed (by DSM-IV criteria) with schizophre-
nia, bipolar disorder or MDD, and controls (Torrey et al., 2000).
In each diagnostic group some subjects died by suicide. The
sections provided were quite rostral, and tissue from ten sub-
jects did not contain sufficient clearly discernible DRN to be in-
cluded. Table 1 summarises the details of the resulting 50
subjects. Adjacent sections were taken for NeuN and PH8
immunostaining every 1 mm, and 1 section every 500 μm for
5-HT1AR ISH. The experiments described here, were carried
out with ethical approval from Oxfordshire Research Ethics
Committee B (#O02.040). All material was coded by the Stan-
ley Medical Research Institute, and experiments and analyses
conducted blind to diagnostic and other information.
2.2. Immunohistochemistry for NeuN and PH8
The NeuN antibody stains virtually all neuron populations
and is widely used for morphometry (Mullen et al., 1992). It
has the advantage over Nissl stains that glia are not labelled
(Gittins and Harrison, 2004). Incubations were carried out
at a concentration of 1:100 overnight at 4 °C. The PH8Major depression Suicides Non-suicidesa
Mean (SEM) N Mean (SEM) N Mean (SEM) N
30.5 (4.2) 7 27.3 (3.1) 12 20.7 (2.5) 14
30.1 (3.4) 7 26.7 (2.5) 8 26.1 (3.3) 10
35.7 (4.0) 5 32.1 (2.8) 7 30.0 (3.4) 9
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lase) has been successfully used to characterise the seroto-
nergic system in human tissue (Tork et al., 1992), and our
preliminary studies confirmed that the antibody did not
label tyrosine hydroxylase in cells of the substantia nigra or
locus coeruleus under these incubation (3 days at 4°; 1:500)
and fixation conditions (4% paraformaldehyde for 5 min).
Staining was performed using a secondary biotinylated anti-
body, avidin-biotin peroxidase complex, and 3,3′-diamino-
benzidine. Omission of the primary antibody was used as a
negative control. See Supplementary Methods for additional
details of the immunohistochemical protocols.
2.3. Cell counting and morphometry
Measurements were grouped by rostrocaudal level in the
rostral DRN (Baker et al., 1990; Paxinos and Huang, 1995) as
delineated by adjacent PH8 and NeuN-stained sections. Given
the heterogeneity in the length and availability of the DRN,
slides were assigned an anatomical level based upon features
present in the section. Three levels were thus identified
(Fig. 1). Level 1 is the rostral pole (DRr) of the DRN, at the
level of the oculomotor nucleus; Level 2 lies between the cau-
dal pole of the oculomotor nucleus and the rostral end of the
trochlear nucleus and contains the dorsal (DRd), ventral
(DRv) and interfascicular (DRif) subnuclei; at Level 3 the
DRN is at its greatest width, with the ventrolateral subnu-
cleus (DRvl) present in addition to the DRd, DRv and DRif.
PH8 stainingwas very dense and prevented resolution of the
cell nucleus, so neuronal profiles were counted. Profiles smaller
than 1 μm diameter were not counted. Neuronal counting with
NeuN staining included only those cells with a visible nucleus.
Measurements were undertaken using the CAST 2.0 stereology
system (Olympus Danmark A/S, Albertslund, Denmark) with
an Olympus BX50 microscope and a one-chip colour CCD cam-
era (TK-C138; JVC, Tokyo, Japan). Overall DRN and subnucleus
cross-sectional area was also recorded. Cell size and staining in-
tensity were measured using the MCID Elite v7.0 imaging sys-
tem (Interfocus, Linton, UK) and a cooled CCD camera (SPOT
RT Slider-2000;Diagnostic Instruments, USA) on aNikon Eclipse
E600 microscope. To determine size, cells were only measured
where the whole cell outline was complete and well defined.Fig. 1. PH8 immunohistochemistry at the three rostrocaudal DRN ‘Levels’ defined in the
dal to Level 1, and Level 3 is 2 mm caudal to Level 2. Abbreviations: Aq: aquaduct; mlf:
ventral subnucleus; DRif: interfascicular subnucleus; DRvl: ventrolateral subnucleus. SSection thickness in the z-axis was measured using a microca-
tor. The use of pre-cut thin frozen sections precluded the use
of empirical or dissector stereological methods, so two-
dimensional counts of PH8 profiles were corrected for split
cells using the Abercrombie (1946) method on a subnucleus-
by-level basis for each subject. Abercrombie correction was
not used for NeuN, given the small size of cell nuclei relative to
section thickness. See Supplementary Methods for additional
details of cell counting protocols.
2.4. Regional and cellular in situ hybridization for 5-HT1AR mRNA
ISH followed themethod of Burnet et al. (1995a), detailed in
SupplementaryMethods, and used two 35S-labelled oligonucle-
otides. Hybridized sections were apposed to X-ray film (Biomax
MR; Kodak, USA) for three weeks with 14C microscales. For cel-
lular analysis, sections were dipped in photographic emulsion
(LM-1; Amersham Pharmacia Biotech, UK) mixed 2:1 with 2%
glycerol, dried overnight, stored at 4 °C for seven weeks, devel-
oped in diluted Phenisol (Ilford, USA), cleared in 2% acetic acid,
fixed in 30% sodium thiosulphate, and lightly stainedwith cresyl
violet.
Densitometric analysis of autoradiographic filmswas carried
out using the MCID system and a cooled CCD camera
(CoolSNAPcf; Photometrics, USA) with a light box, and shading
correction. The DRN was delineated and the integrated density
measured with greyscale values converted into nCi/g tissue
equivalents using a standard curve determined from the 14 C
microscale. These values were corrected for local background.
The cross-sectional area of DRN signal was measured.
Emulsion-dipped sections were analysed in subnuclei of the
DRN with the MCID microscope system, using a 20× objective,
delineating 5-HT1AR mRNA-positive cells under light-field con-
ditions and measuring the corresponding optical density of
overlying silver grains under dark-field illumination. These
measures were corrected for local background.
2.5. Statistical analysis
All statistical analyses were carried out in SPSS 13.0 with a
per-test type I error rate of 5%. Tests were carried out at the
three DRN rostrocaudal levels, using the mean value for alltext. All three images are from the same subject, inwhom Level 2 is 1 mm cau-
medial longitudinal fasciculus; DRr: rostral pole; DRd: dorsal subnucleus; DRv:
cale bar: 1 mm.
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for all subnuclei combined; for subnucleus-specific findings
(Levels 2 and 3) see Supplementary Material. Ideally a
repeated-measures ANOVA would be used, however, this was
not feasible, as many subjects did not have values for all levels.
Therefore, the analysis was done ‘per level’, with planned com-
parisons of the control subjects versus the three other diagnostic
groups using ANOVA. To analyse effects of suicide, subjects were
divided into three groups: controls (none of whom died by sui-
cide), patients who committed suicide, and patients who did
not. Statistically significant correlations with demographic and
confounding variableswere included in an analysis of covariance
(ANCOVA), with a non-parametric rank-transform ANCOVA
where appropriate (see Supplementary Methods).
3. Results
3.1. Normative data
Fig. 1 shows the distribution of PH8-immunoreactive 5-HT
neurons within the DRN and its subnuclei at the three rostro-
caudal levels studied. Neuronal types were consistent with
those found previously (Baker et al., 1990, 1991; Baumann et
al., 2002), including large round neurons in the ventral subnu-
cleus (DRv) (with some in the interfascicular subnucleus
[DRif]), elongated fusiform cells in the DRif, large ovoid neu-
rons in the dorsal subnucleus (DRd), and small ovoid and trian-
gular neurons found in all subnuclei. Neuronal distributions
were also broadly similar to prior reports (Baker et al., 1990,
1991; Baumann et al., 2002; Bielau et al., 2005; Underwood etFig. 2. Rostrocaudal gradients across the human DRN. For definitions of the three an
by the extent of NeuN immunostaining (squares), and the extent of 5-HT1AR mRNA
(triangles) and PH8 (squares). C: Cross-sectional area of cells immunolabelled by N
as measured on film autoradiograms (left axis, squares) and per cell (right axis, trian
for the control group alone (data not shown).al., 1999), except that the density of cells in the ventrolateral
subnucleus (DRvl) appears to be much less in our study than
found by Baker et al. (1990, 1991).
Across all subjects, DRN area, defined either by extent of
NeuN and PH8 immunostaining or 5-HT1AR mRNA signal, in-
creased from Level 1 to Levels 2 and 3 (Fig. 2A; all pairwise
comparisons pb0.05). The area of the DRN correlated with
fresh brain weight across all subjects (Level 2 r=0.48,
pb0.01; Level 3 r=0.43, p=0.05). For area of DRN subnuclei
at each level, see Supplementary Table 1.
PH8 immunopositive cell density increased from Level 1 to
Level 3 (Fig. 2B; all pairwise comparisons pb0.01), while NeuN
cell density showed a less marked increase (Fig. 2B; significant
difference between Levels 1 and 3, pb0.05), indicating that the
proportion of serotonergic neurons increases rostrocaudally
within the DRN. See Supplementary Tables 2 and 3 for PH8
and NeuN cell densities in each subnucleus at each level.
Themean size of NeuN-stained neurons increased fromLevel
1 to Level 3 (Fig. 2C; significant between Level 1 and the other
levels, pb0.01; Supplementary Table 5), but with no significant
variation for PH8-immunopositive cells. For subnucleus-
specific data on cell size, see Supplementary Tables 4 and 6.
The intensity of DRN 5-HT1AR ISH signal increased from
Level 1 to Level 3 (Fig. 2D), paralleling the increasing propor-
tion of cells that are PH8 positive (Fig. 2B), but the signal in-
tensity per cell did not change between levels (Fig. 2D).
There were no correlations between study measures and
age, pH, PMI, freezer storage time, gender, history ofmedication
or substance misuse, or onset and duration of illness except
where mentioned below.atomical levels, see text and Fig. 1. A: Cross-sectional DRN area, as measured
hybridization signal (triangles). B: Density of cells immunolabelled by NeuN
euN (triangles) and PH8 (squares). D: Relative abundance of 5-HT1AR mRNA,
gles). Each panel shows the average for all subjects; similar profiles are seen
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Two differences in DRN area were seen between groups
(Fig. 3). First, DRN area was reduced in subjects with MDD
compared to controls at Level 2 (planned contrast, p=0.05)
and Level 3 (ANOVA pb0.05; planned contrast, pb0.05).
The reduction was apparent in all subnuclei at this level
(Supplementary Table 1). Second, at Level 1, DRN area was
increased in patients committing suicide compared to other
patients (Kruskal–Wallis [KW] ANOVA pb0.05; Wilcoxon–
Mann–Whitney [WMW] suic>non-suic pb0.05); inspection
of Fig. 3A indicates that this difference is seen across diagnos-
tic groups). Including brain weight as a covariate in analyses
eliminated the significance of the reduction of Level 2 DRN
area in MDD (ANCOVA p=0.53; planned contrast, p=0.18)
and Level 3 (ANCOVA p=0.09; planned contrast p=0.10)Fig. 3. Cross-sectional area of the DRN, as delineated by immunostaining, at
the three rostrocaudal levels, grouped by diagnosis. A: Level 1. B: Level 2.
C: Level 3. At Level 1, patients are also separately grouped together by the
presence or absence of suicide. Filled markers show non-suicides, and
unfilled symbols show suicides. *pb0.05.but the increased area in suicide survived (rank-transform
ANCOVA p=0.03; planned contrasts pb0.05).
3.3. Neuronal density in the DRN
Abercrombie corrected PH8 immunopositive cell counts did
not reveal any diagnostic differences (Fig. 4). At Level 2, PH8
cell density was increased in patients committing suicide ver-
sus non-suicides (planned contrast, pb0.05; Fig. 4B). PH8 cell
density at Level 2 correlated with post-mortem interval (rs=
−0.38, pb0.05) and the comparison became a non-
significant trend when this was included as a covariate
(p=0.055), but became significant for suicides versus controls
(planned contrast, pb0.05). NeuN cell density significantly cor-
related with PH8 cell density (r=0.38, pb0.0005) but did not
differ by diagnosis at any level (Table 2). NeuN cell density in-ig. 4. Density (cells/mm2) of PH8-immunopositive cells in the DRN at the
ree rostrocaudal levels, grouped by diagnosis. Black symbols show non-
icides, and white symbols show suicides. A: Level 1. B: Level 2. C: Level
. At Level 2, patients are also separately grouped together by the presence
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pb0.05; Level 2 r=−0.38 pb0.05; Level 3 r=−0.45 pb0.05),
pH (Level 1 r=0.51 pb0.01; Level 2 r=0.39 pb0.05), and
post-mortem interval (Level 3 r=−0.49 pb0.05). Inclusion
of these factors as covariates did not affect the results. See Sup-
plementary Tables 2 and 3.
3.4. Neuronal soma size in DRN
At Level 1 the area of PH8 neuronswas less in bipolar disor-
der subjects compared to controls (KWANOVA pb0.05;WMW
bipbcon pb0.01; Fig. 5) and decreased in suicides versus con-
trols (KW ANOVA pb0.05; WMW suicbcon pb0.05; Fig. 5).
Freezer storage time correlated with PH8 cell area at Level 1
(rs=−0.33, pb0.05) and Level 2 (r=−0.37, pb0.05); with
freezer storage time as covariate the reductions in cell size at
Level 1 seen in bipolar disorder and suicide groups remainedFig. 5. Cross-sectional area (μm2) of the soma of PH8-immunopositive cells
in the DRN at the three rostrocaudal levels, grouped by diagnosis. A: Leve
1. B: Level 2. C: Level 3. At Level 1, patients are also separately grouped to-
gether by the presence or absence of suicide. Black symbols show non-
suicides, and white symbols show suicides. **pb0.01.
Fig. 6. A: Cellular localization of 5-HT1AR mRNA in the human DRN. B: Sense
strand control, showing low level of background labelling. Sections counter-
stained with cresyl violet. Scale bar=50 μm.lsignificant. There were no differences in NeuN-
immunoreactive cell size. See Supplementary Tables 4–6.
3.5. 5-HT1AR mRNA abundance in DRN and DRN neurons
The spatial extent of 5-HT1AR mRNA signal correlated with
DRN area delineated by immunostaining (r=0.68, pb0.001),
and replicated the significant reduction in DRN area at Level 2
in subjects with MDD (planned contrast, pb0.05) but not at
Level 3 (data not shown). Emulsion-dipped sections revealed
that hybridization signal for 5-HT1AR mRNA was concentrated
over large cells, putatively 5-HT neurons (Austin et al., 1994;
Fig. 6), with no clear differences in cellular grain density be-
tween DRN subnuclei (Supplementary Table 7).
DRN 5-HT1AR mRNA film signal correlated inversely with
post-mortem interval (Level 2, r=−0.35 pb0.05; Level 3,
r=−0.41 pb0.05), and positively with pH (Level 3,
r=0.48 pb0.01). With these factors as covariates, DRN 5-
HT1AR mRNA signal did not differ between diagnostic groups
nor by suicide status (Table 3). The expression of 5-HT1AR
mRNA per cell within the DRN correlated with the overall
DRN hybridization signal intensity (r=0.37, pb0.05); it
also related inversely with freezer storage time (Level 1
rs=−0.49 pb0.05; Level 2 rs=−0.41 pb0.05; Level 3 rs=
Table 3
5-HT1AR mRNA signal in the DRN measured with film autoradiography.
Controls Schizophrenia Bipolar disorder Major depression Suicides Non-suicidesa
Level Mean (SEM) N Mean (SEM) N Mean (SEM) N Mean (SEM) N Mean (SEM) N Mean (SEM) N
1 9.9 (1.1) 4 7.6 (2.2) 4 20.8 (5.9) 2 9.3 (1.4) 7 13.2 (2.7) 7 7.4 (1.2) 6
2 18.9 (1.4) 11 15.9 (2.6) 8 17.1 (2.4) 7 20.6 (1.9) 10 20.2 (1.9) 13 15.9 (1.6) 12
3 32.0 (2.3) 8 22.9 (5.3) 8 25.9 (5.3) 6 38.7 (4.2) 7 31.1 (4.3) 10 27.1 (4.6) 11
Values are nCi/g tissue equivalents. There are no significant differences between groups.
a Excludes normal controls.
131P.R. Matthews, P.J. Harrison / Journal of Affective Disorders 137 (2012) 125–134−0.38 pb0.05) and post-mortem interval (Level 2 rs=
−0.42 pb0.05; Level 3 rs=−0.44 pb0.05), and positively
with pH (Level 3 rs=0.56 pb0.01). The grain density of
dipped sections differed in the DRN taken as a whole at
Level 3 (WMW bipbcon pb0.05) but became non-significant
when freezer storage time, PMI, and pH were added as covari-
ates (Supplementary Table 7 and Supplementary Figs. 5–7).
4. Discussion
A role for 5-HT in mood disorders and in suicide has long
been suspected, and neuropathological studies of the DRN
have been one manifestation of this interest. However, to
date, the studies have had several limitations, most notably
their small sample size, and also the fact that in most studies
(except two studies of late life depression: Hendricksen et al.,
2004; Syed et al., 2005), virtually all mood disorder subjects
died by suicide, meaning that the possibility of differential ef-
fects of diagnosis andmode of death could not be disentangled.
This study attempted to overcome some of these limitations
by using a larger sample, and by including subjects with mood
disorders who did not die by suicide, and suicide victims who
had schizophrenia. In this way we hoped to parse the effects
of diagnosis from those of suicide. And, we used three comple-
mentary indices to assess DRN status: NeuN as a marker of all
neurons; PH8 immunostaining for 5-HT neurons, and 5-
HT1ARmRNA in situ hybridization as another means to identify
5-HT neurons and their expression of this key inhibitory auto-
receptor. Our main findings are that: 1) suicide is associated
with an increased DRN area and with an increased density
and decreased size of serotonergic neurons; 2) in MDD, DRN
area is decreased, with no differences in cell density or size,
and 3) in bipolar disorder, serotonergic neuron size is de-
creased. These findings were limited, in terms of anatomical
extent or robustness to confounding factors.We foundno alter-
ations in schizophrenia, and nodiagnosis- or suicide-associated
differences in 5-HT1AR mRNA expression.
4.1. Differences in DRN area and cell composition in suicide and
mood disorders
Subjects committing suicide showed an increased area of
the rostral pole (Level 1) of the DRN (with decreased seroto-
nergic cell size and no change in cell density) and an in-
creased TPH-immunoreactive (i.e. serotonergic) cell density
more caudally (Level 2) within the rostral DRN. The latter
agrees with a finding by Underwood et al. (1999) in suicide
victims most of whom had MDD; another group have
reported a similar observation in suicide victims with eitherunipolar or bipolar disorder which was limited to the ventro-
lateral subnucleus (Baumann et al., 2002; Bielau et al., 2005).
Note that we did not find a corresponding increase in total
neuronal density as measured by NeuN, and that the defini-
tion of a cell type as ‘serotonergic’ is relative and not abso-
lute, since it is affected by the abundance of the marker
being used. Thus, it is noteworthy that suicide victims have
increased DRN levels of TPH immunoreactivity (Boldrini et
al., 2005), and of TPH2mRNA (Bach-Mizrachi et al., 2006), in-
cluding a greater abundance per neuron (Bach-Mizrachi et
al., 2008). A parsimonious interpretation is therefore that sui-
cide is associated with increased TPHwhich leads to a greater
number of neurons being labelled as serotonergic, rather
than more serotonergic neurons per se. In turn, it has been
speculated that the up-regulation of TPH reflects a homeo-
static response to impaired serotonin transmission in suicide
(Bach-Mizrachi et al., 2006, 2008; Boldrini et al., 2005), espe-
cially when alterations in 5-HT1AR and 5-HT transporter ex-
pression are considered as well (Arango et al., 2001;
Boldrini et al., 2008). However, these conclusions remain
provisional, since another group found no difference in TPH
immunoreactivity in suicide victims (Bonkale et al., 2004).
Likewise, our finding of a decreased size of serotonergic neu-
rons in rostral DRN in suicide victims may suggest a de-
creased axodendritic arborisation or activity, but requires
replication since it was not observed by Underwood et al.
(1999) or Arango et al. (2001).
Positive findings related to diagnosis weremodest, and their
interpretation hampered by the lack, noted earlier, of compara-
ble studies in which diagnostic effects were studied indepen-
dent of suicide. In MDD, we found the cross-sectional area of
the DRN was decreased, without changes in cell size or density.
This suggests a reduction in the neuropil, which is mainly com-
prised of glia, dendrites, axons, and vascular elements. In the ce-
rebral cortex, several studies have reported glial decreases in
MDD (e.g. Cotter et al., 2001; Gittins and Harrison, 2011;
Öngür et al., 1998; Rajkowska et al., 1999), and amorphometric
study of glia in the DRNwould be of interest. Unchanged seroto-
nergic neuronal density and size in DRN has also been reported
in the two existing studies of elderly subjects with unipolar de-
pression (Hendricksen et al., 2004; Syed et al., 2005). In bipolar
disorder, we found serotonergic neurons in the rostral DRN to
be decreased in somal area; this is reminiscent of studies show-
ing that the size of some cortical neuron populations is reduced
in the disorder (see Harrison, 2002). In schizophrenia, our neg-
ative findings for neuronal density and size replicated the one
previous study (Craven et al., 2005), and we also found DRN
area to be unaltered. As such, any serotonergic involvement in
schizophrenia pathophysiology does not appear to includemor-
phometric changes in the DRN.
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and schizophrenia
The extent of 5-HT1AR mRNA distribution was decreased
in MDD, consistent with the reduced DRN area measured
immunohistochemically, and in agreement with a reduced
extent of 5-HT1AR binding seen in an earlier study (Arango
et al., 2001; Boldrini et al., 2008). However, we found no dif-
ferences in 5-HT1AR mRNA abundance within the DRN (ei-
ther overall or per neuron), in any diagnostic group, nor in
suicide victims, suggesting that the expression of this key in-
hibitory autoreceptor is not altered in these conditions. To
our knowledge this is the first study of this kind, although
Anisman et al. (2008) state (without presenting the data)
that they also found no alteration in subjects with depression
or following suicide, and Goswami et al. (2010) found no
alterations in 5-HT1AR mRNA from laser-capture microdis-
sected DRN serotonergic neurons in MDD. In contrast, 5-
HT1AR mRNA is decreased in the frontal cortex and
hippocampus of MDD subjects in the present brain series
(Lopez-Figueroa et al., 2004). The lack of a parallel (or recip-
rocal) change in the DRN is reminiscent of other situations, in
which expression of the 5-HT1AR autoreceptor is unaltered
despite changes in the post-synaptic 5-HT1AR population
(e.g. after electroconvulsive shock; Burnet et al., 1995b).
Studies of DRN 5-HT1AR binding in depressed suicides have
given variable results, but with some evidence for increased
binding rostrally and decreased binding caudally (Arango et
al., 2001; Boldrini et al., 2008; Stockmeier et al., 1998). Al-
tered 5-HT1AR binding with no change in encoding mRNA
has been observed previously, and may reflect a prominent
post-transcriptional component to receptor regulation
(Burnet et al., 1996).
4.3. Limitations
Despite being the largest study of its kind, our work has
several limitations. Most importantly the extent of the tissue
and the characteristics of the sections. The whole DRN was
not sampled; thus, although most neurons, of the DRN are
found in the rostral subdivisions sampled here (Baker et al.,
1990), estimates of DRN volume and cell number are not pos-
sible. And, since not all subjects had tissue from all three an-
atomical levels of the DRN, the rostrocaudal length of the
DRN and its subnuclei could not be determined, and anatom-
ical level could not be included in a repeated-measures
ANOVA. Finally, given the thickness of the sections (14 μm
before processing, ~6 μm once stained) three-dimensional
counting procedures were not possible, requiring two-di-
mensional ‘non-stereological’ methods, which have inherent
limitations. For example, although we used the Abercrombie
correction for PH8 cell counts, this is imperfect and does not
control for ‘lost caps’ (Hedreen, 1998), and the corrected cell
densities will remain somewhat inaccurate due to the large
and heterogeneous size of DRN neurons (Guillery and
Herrup, 1997). However, for comparative studies between
groups, this should not bias the profile counts unless there
are corresponding and marked differences in cell size
(which did not prove to be the case; if anything, the de-
creased cell size in suicide will have mitigated against finding
an increased cell density).A second weakness is the limited information available
regarding medication and substance misuse. Quantitative es-
timates of lifetime exposure were available for antipsy-
chotics, but only dichotomous (yes/no) information was
available about antidepressants and mood stabilizers. It is
therefore possible that some of our findings, both positive
and negative, may have been confounded by these drugs.
Such confounding is most plausible for the 5-HT1AR mRNA
data, since expression of this receptor is known to be altered
by various depression treatments (Burnet et al., 1994, 1995b,
1999; Chen et al., 1995). Similarly, PH8 immunostaining
could be affected by antidepressant-induced alterations in
abundance of TPH isoforms (Bielau et al., 2005; Shishkina et
al., 2007; Yang et al., 2010). There is an association between
smoking, suicide, and low serotonergic markers (Malone et
al., 2003) but we did not have smoking data for these sub-
jects to examine the relationship. There is also an association
between alcoholism and decreased serotonin transmission
(Fahlke et al., 2011), although there is no evidence of seroto-
nergic neuron loss or change in cell size in the DRN in alco-
holism (Baker et al., 1996; Underwood et al., 2007), and we
did not find any effect of substance, including alcohol,
misuse.
Thirdly, our data highlight the potential sensitivity of
morphological and immunocytochemical indices to peri-
and post-mortem variables, including pH, post-mortem in-
terval and freezer storage time (Harrison et al., 1995). Such
factors are well appreciated in molecular studies, but not al-
ways considered in morphometric and immunohistochemi-
cal ones.
4.4. Conclusions
We found evidence for modest alterations in DRN mor-
phology in suicide, MDD, and bipolar disorder. These data
add to the evidence that the serotonergic involvement in
mood disorder and suicide includes a presynaptic and ‘neuro-
pathological’ component. Our finding of differential effects of
MDD and suicide provides one explanation for why previous
studies (which have confounded the two) have had inconsis-
tent findings. Together with the apparent anatomical hetero-
geneity of changes, the findings indicate that further progress
will require larger studies, of the complete DRN, from sub-
jects who are well characterised clinically and demographi-
cally, and which also measure and take account of a range
of confounding variables.
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